Key result
Inhaled xenon blunts chemotherapy-induced hs-cTnT rise by ~8 pg/mL compared to control.
Why the study?
Does inhalation of subanesthetic doses of xenon (27-34%) reduce the increase in high-sensitivity cardiac troponin T and other organ damage markers at Day 15 in women with breast, ovarian, or uterine corpus cancer receiving systemic anticancer therapy?
RCT (n=44)
Double-blind (patients, outcome assessors, and data analysts blinded; anesthesiologist administering inhalations unblinded)
1:1 computer-generated random number sequence with sequentially numbered opaque sealed envelopes
No
Does inhalation of subanesthetic doses of xenon (27-34%) reduce the increase in high-sensitivity cardiac troponin T and other organ damage markers at Day 15 in women with breast, ovarian, or uterine corpus cancer receiving systemic anticancer therapy?
In this small exploratory RCT, subanesthetic xenon inhalations during systemic chemotherapy were well tolerated and attenuated early increases in high-sensitivity cardiac troponin T and LVEF decline at 15 days compared to control.
Answers are grounded in this paper and cite their sources.
Xenon may mitigate early chemotherapy cardiotoxicity; extends preclinical protection to randomized evidence in oncology.
INTRODUCTION: Organ toxicity of anticancer treatment remains a significant problem in comorbid patients. Xenon has organoprotective properties, but its clinical use during chemotherapy has been insufficiently studied. OBJECTIVE: To assess changes in organ damage markers, as well as the safety and tolerability of inhaled subanesthetic xenon in patients receiving systemic anticancer therapy. MATERIALS AND METHODS: A prospective randomized controlled study was conducted. Forty-four women with breast, ovarian, or uterine corpus cancer were randomized; 41 completed the intervention stage and were analyzed: 20 in the xenon group and 21 in the control group. The xenon group received three 30-minute inhalations of an oxygen-xenon mixture containing 27–34 % xenon on Days 1, 3, and 5 from chemotherapy initiation; controls received oxygen-nitrogen inhalations. The primary outcome was change in high-sensitivity cardiac troponin T from baseline to Day 15. Secondary outcomes included N-terminal pro-B-type natriuretic peptide (NT-proBNP), S100B protein, syndecan-1, echocardiographic parameters, kidney and liver function tests; safety was assessed by adverse events. RESULTS: Change in high-sensitivity cardiac troponin T from baseline to Day 15 was 8.94 [4.50; 13.30] pg/mL in the control group and 1.01 [−0.09; 1.98] pg/mL in the xenon group (p < 0.001). In the baseline-adjusted model, the between-group difference at Day 15 was β = −7.90 (95% CI: −12.85; −2.94; p = 0.003). The adjusted between-group difference in left ventricular ejection fraction change was +4.66 % (95% CI: 2.4; 6.9; p < 0.001). Significant within-group changes in NT-proBNP and S100B were observed in the control group, whereas no significant changes were observed in the xenon group. CONCLUSIONS: Three 30-minute inhalations of an oxygen-xenon mixture containing 27–34 % xenon were well tolerated and were associated with preliminary differences in changes in markers of subclinical organ damage. These findings require confirmation in larger studies with longer follow-up.
No takes yet. Share an insight, caveat, or question.
Евгеньевич et al. (2026) conducted an RCT in Breast, ovarian, or uterine corpus cancer receiving systemic anticancer therapy (n=44). Inhaled oxygen-xenon mixture vs. Inhaled oxygen-nitrogen mixture (50% oxygen) on Days 1, 3, and 5 was evaluated on Change in high-sensitivity cardiac troponin T (hs-cTnT, pg/mL) from baseline to Day 15 (MD -7.90 pg/mL, 95% CI -12.85 to -2.94, p=<0.001 (unadjusted); 0.003 (baseline-adjusted ANCOVA)). Inhaled subanesthetic xenon attenuated the Day-15 rise in hs-cTnT compared to control during chemotherapy.
Synapse has enriched 10 related papers. Consider them for comparative context: